Santé Biotech : What industrial use of stem cells ?

La Fondation Pierre-Gilles de Gennes pour la Recherche
et
Agro Santé Biotech

vous invitent à la conférence du

Dr. Davide Danovi (UCL Cancer Institute, London)

sur le thème

What industrial use of stem cells ?
(conférence en anglais)

Le jeudi 16 juin 2011 à 18h45
Fondation Pierre-Gilles de Gennes – 29, rue d’Ulm – Paris 5e

A stem cell is defined as capable to replicate into exact copies of itself (self-renewal) or to generate functionally different cells (differentiation). We hear a lot about the use of stem cells to improve public health in different ways. Nonetheless, it is often difficult to distinguish between established applications and vane promises, medical science, business and the edge of research. As the field explodes in many directions, it is beginning to be possible to define more clearly what can be actually achieved with stem cells in the near future and what remains in the books of bench scientists or even in the realm of future possibilities. The talk will briefly introduce the emerging use of stem cells in regenerative medicine, cell therapy and drug screening and will present a case study applications of stem cell science to isolate therapeutics for brain tumours.

Davide Danovi obtained his Medical degree at the University of Milan, Italy where he also had his PhD at the European Institute of Oncology, one of the biggest comprehensive cancer center in Europe. There, he developed an interest in neoplastic transformation and demonstrated the causative role of the HdmX protein in human cancer. He then became an EMBO fellow and subsequently joined the laboratory of Prof. Austin Smith at the Wellcome Trust Centre for Stem Cell Research in Cambridge. Here, he has taken forward the pioneering work of Dr. Steve Pollard on glioma neural stem cells. With him at the UCL Cancer Institute in London he is now further developing a live image based chemical screening platform on adherent neural stem cells from brain tumours, cell lines mirroring the elusive tumour initiating cells to which drug screens should be directed.

Inscription par mail à l'attention d'Elettra Baldacci - ebi@fondation-pgg.org